Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Interferon regulatory factor 7 (IRF7) is a member of the interferon regulatory factor family of transcription factors, encoded by the *IRF7* gene on human chromosome 11p15.5[2][4]. IRF7 plays a critical role as the "master regulator" of type I interferon (IFN-I) induction downstream of pathogen recognition receptors (PRRs), especially in response to viral infection[2][3][6]. Upon detection of pathogenic nucleic acids by PRRs, IRF7 is phosphorylated by kinases such as TBK1 and IKKε, dimerizes, and translocates to the nucleus where it activates transcription of type I interferon genes—including multiple IFN-α genes[3][5][6]. IRF7 is constitutively expressed in lymphoid tissues such as the spleen, bone marrow, and particularly in plasmacytoid dendritic cells, but it is inducible in many other cell types[2][4]. Beyond antiviral defense, IRF7 regulates diverse biological processes including autophagy, apoptosis, and cell proliferation; it acts both through IFN-I dependent and independent pathways[2][3]. IRF7 activity and expression are regulated by complex post-translational modifications, including phosphorylation, ubiquitination, and acetylation, which tightly control its activation potential and function[1][6]. IRF7 plays significant roles in the pathogenesis and modulation of infectious diseases, cancer (acting as either suppressor or promoter depending on context), inflammatory conditions, and autoimmune diseases[2][3][7]. Aberrant or excessive IRF7 activity has been implicated as a contributor to autoimmunity and certain cancer phenotypes[2][3]. Several splice variants exist (IRF7A, IRF7B, IRF7C, IRF7H), each with distinct regulatory properties and potential roles in immunity and disease[1][2]. IRF7 interacts with other IRF family members, such as IRF3, and with negative regulators like AIP[4][5]. To date, IRF7 itself does not have direct small molecule drugs or inhibitors in clinical use, but it is regarded as a druggable target for antiviral and immunomodulatory therapies[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interferon regulatory factor 7 (IRF7).